pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL MYERS SQUIBB · news · pharmadog
← back to BRISTOL MYERS SQUIBB
News mentioning BRISTOL MYERS SQUIBB
305
stories
21d
Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
fiercebiotech
22d
Q3 layoffs down YOY, with 90% fewer biopharma employees affected
biospace
22d
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
biopharma dive
22d
TCGX launches $600M fund to bankroll Asian biotechs
fiercebiotech
23d
5 biggest venture capital raises of Q3 2026
biospace
23d
CAR-T biotech Caribou makes ‘heartbreaking’ call to shrink headcount, halt pipeline
fiercebiotech
23d
Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune disease
fiercebiotech
23d
Compliance concerns hinder rollout of AI in drug manufacturing: Survey
biospace
24d
BioSpace 40 Under 40 winners make their mark on biopharma
biospace
24d
Senior Leerink analyst downgrades Bristol Myers, citing pipeline fears
endpoints
24d
Significant stock movers of September: Viking soars, Longeveron slides
biospace
24d
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
24d
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
27d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
27d
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
28d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
28d
BMS reports liver injury events in lung disease program, with key readout near
biospace
28d
Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshaken
fiercebiotech
29d
Patient death raises liver questions ahead of Bristol Myers readout
endpoints
29d
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
biopharma dive
29d
$40M in tax incentives expected to generate 1,600+ life sciences jobs in Massachusetts
biospace
Sep 30, 26
Biopharma needs to reward scientists' judgment
biospace
Sep 30, 26
Biopharma needs to reward scientists' judgment
biospace
Sep 29, 26
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
Sep 29, 26
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
Sep 29, 26
Biopharma recruiters see ‘signs of recovery’ as layoffs remain cool in Q3’26
fiercebiotech
Sep 29, 26
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
Sep 28, 26
ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’
fiercebiotech
Sep 28, 26
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
biopharma dive
Sep 28, 26
Scynexis' BARDA alliance; Bristol Myers' early data for dual-targeting CAR-T
endpoints
← prev
page 3 of 11
next →
